Abstract

Immunomodulation
activity-guided fractionation of ethanol extract of Brugmansia suaveolens leaves was carried out to isolate a novel
compound SUPH036-022A (1) by
co-culturing test fraction/compound activated PBMC with MCF7 and A549 cancer cell
lines. Assessment of immune markers in PBMC, and analysis of apoptosis markers
and cell cycle was carried out for cancer cells. The structure of the isolated
compound was elucidated by spectral analysis. Compound 1 enhanced secretion of immune markers, IL-2 and IFN-γ, from PBMC. Further,
compound 1 treated PBMC increased
cell death in MCF7 and A549 cell lines and induced ROS production and
mitochondrial membrane perturbation, leading to apoptosis. Flow cytometry
analysis revealed that compound 1
stimulated PBMC cause five-fold increase in cell cycle perturbations in the
sub-G1 stage of cancer cells as compared to negative control, while compound
itself had weak cytotoxicity against tested cell lines. Compound 1, increases secretion of immune
markers in PBMC inducing apoptosis in co-cultured MCF7 and A549 cancer cells
while compound itself had weak cytotoxic activity against these cell
lines.  Compound 1 is a novel lead for immunomodulation-mediated anticancer
activity.